Drug Profile
Ningetinib - HEC Pharm
Alternative Names: CT-053; CT-053-PTSA; Ningetinib toluenesulfonate; Ningetinib tosylateLatest Information Update: 07 Nov 2022
Price :
$50
*
At a glance
- Originator HEC Pharm
- Developer HEC Pharm; Jiangsu Alphamab Biopharmaceuticals; Sunshine Lake Pharma
- Class Antineoplastics; Pyrazoles; Quinolines; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto-oncogene protein c-mer inhibitors; Proto-oncogene protein c-met inhibitors; RON protein inhibitors; Signal transduction pathway modulators; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Liver cancer; Non-small cell lung cancer; Renal cancer
- No development reported Acute myeloid leukaemia
- Discontinued Glioblastoma
Most Recent Events
- 28 Oct 2022 Jiangsu Alphamab Biopharmaceuticals terminates (phase I/II trial in Liver cancer in China (NCT04601610)
- 05 Aug 2021 Sunshine Lake Pharma plans a phase II trial in Non-small cell lung cancer (Late-stage disease) (PO) (NCT04992858)
- 07 Jun 2021 Phase-I/II clinical trials in Liver cancer (In adults, In the elderly, Late-stage disease, Combination therapy) in China (unspecified route)(NCT04601610)